Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy

Symbols: ONXX
Share

Goldman Sachs has upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to CL-Buy and has added the company to its Americas Conviction List. Price target has been raised from $45 to $47.


 
 
< Previous
Deutsche Bank Upgrades Skyworks to Buy
Next >
BMO Capital Markets Upgrades MeadWestvaco to Outperform
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust